RIGEL PHARMACEUTICALS, INC. Revenue Breakdown
No Revenue Breakdown for RIGL on this site yet.
- 2025-12-31: Others Not split by product in the filing$294.28M100.00%; Total revenue $294.28M.
- 2024-12-31: Others Not split by product in the filing$179.28M100.00%; Total revenue $179.28M.
- 2023-12-31: Others Not split by product in the filing$116.88M100.00%; Total revenue $116.88M.
- 2022-12-31: Others Not split by product in the filing$120.24M100.00%; Total revenue $120.24M.
Source checked: the stored Revenue Breakdown page for RIGL.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $294.28M 100.00% | $294.28M |
| 2024-12-31 | Not split by product in the filing $179.28M 100.00% | $179.28M |
| 2023-12-31 | Not split by product in the filing $116.88M 100.00% | $116.88M |
| 2022-12-31 | Not split by product in the filing $120.24M 100.00% | $120.24M |
| 2021-12-31 | Not split by product in the filing $149.24M 100.00% | $149.24M |
| 2020-12-31 | Not split by product in the filing $108.62M 100.00% | $108.62M |
| 2019-12-31 | Not split by product in the filing $59.29M 100.00% | $59.29M |
| 2018-12-31 | Not split by product in the filing $44.51M 100.00% | $44.51M |
| 2017-12-31 | Not split by product in the filing $4.48M 100.00% | $4.48M |
| 2016-12-31 | Not split by product in the filing $20.38M 100.00% | $20.38M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $78.70M 100.00% | $78.70M |
| 2026-03-31 | Not split by product $58.82M 100.00% | $58.82M |
| 2025-12-31 | Not split by product $69.80M 100.00% | $69.80M |
| 2025-09-30 | Not split by product $69.46M 100.00% | $69.46M |
| 2025-06-30 | Not split by product $101.69M 100.00% | $101.69M |
| 2025-03-31 | Not split by product $53.33M 100.00% | $53.33M |
| 2024-12-31 | Not split by product $57.60M 100.00% | $57.60M |
| 2024-09-30 | Not split by product $55.31M 100.00% | $55.31M |
| 2024-06-30 | Not split by product $36.84M 100.00% | $36.84M |
| 2024-03-31 | Not split by product $29.53M 100.00% | $29.53M |
| 2023-12-31 | Not split by product $35.79M 100.00% | $35.79M |
| 2023-09-30 | Not split by product $28.13M 100.00% | $28.13M |
| 2023-06-30 | Not split by product $26.89M 100.00% | $26.89M |
| 2023-03-31 | Not split by product $26.07M 100.00% | $26.07M |
| 2022-12-31 | Not split by product $51.28M 100.00% | $51.28M |
| 2022-09-30 | Not split by product $22.41M 100.00% | $22.41M |
| 2022-06-30 | Not split by product $29.82M 100.00% | $29.82M |
| 2022-03-31 | Not split by product $16.73M 100.00% | $16.73M |
| 2021-12-31 | Not split by product $20.41M 100.00% | $20.41M |
| 2021-09-30 | Not split by product $21.54M 100.00% | $21.54M |
| 2021-06-30 | Not split by product $26.27M 100.00% | $26.27M |
| 2021-03-31 | Not split by product $81.02M 100.00% | $81.02M |
| 2020-12-31 | Not split by product $18.45M 100.00% | $18.45M |
| 2020-09-30 | Not split by product $18.39M 100.00% | $18.39M |
| 2020-06-30 | Not split by product $16.02M 100.00% | $16.02M |
| 2020-03-31 | Not split by product $55.76M 100.00% | $55.76M |
| 2019-12-31 | Not split by product $15.40M 100.00% | $15.40M |
| 2019-09-30 | Not split by product $20.86M 100.00% | $20.86M |
| 2019-06-30 | Not split by product $10.41M 100.00% | $10.41M |
| 2019-03-31 | Not split by product $12.62M 100.00% | $12.62M |
| 2018-12-31 | Not split by product $37.86M 100.00% | $37.86M |
| 2018-09-30 | Not split by product $4.87M 100.00% | $4.87M |
| 2018-06-30 | Not split by product $1.79M 100.00% | $1.79M |
| 2017-09-30 | Not split by product $900.00K 100.00% | $900.00K |
| 2017-03-31 | Not split by product $3.58M 100.00% | $3.58M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |